|
Teva launches asthma treatment inhaler with dose counter
Globes Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) unit Teva Respiratory has launched its ProAir HFA asthma treatment inhaler with a dose counter for use in patients from age four. The inhaler is for the treatment or prevention of … |
View full post on asthma – Google News